Autoimmune hepatitis: the present status in Japan

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Background:

• Autoimmune hepatitis (AIH) is a chronic liver disease with significant morbidity.
• Lupoid hepatitis and lupoid type chronic active hepatitis (CAH) are specific forms of AIH.
• Understanding the epidemiology and treatment outcomes of these conditions is crucial for patient management.

Purpose of the Study:

• To investigate the clinical characteristics, treatment efficacy, and survival rates of lupoid hepatitis and related autoimmune liver diseases.
• To compare the features of lupoid hepatitis with other types of CAH.
• To identify factors influencing the prognosis of autoimmune hepatitis.

Main Methods:

• A nationwide survey of 518 cases of lupoid hepatitis and related diseases from 1975-1982.
• Analysis of patient demographics, liver function tests, treatment regimens (steroids, immunosuppressants), and survival data.
• Comparison of clinical and biochemical profiles across different types of CAH.

Main Results:

• Autoimmune hepatitis was more prevalent in females; male cases of B type CAH with high gamma-globulin outnumbered females.
• Lupoid hepatitis and lupoid type CAH showed similar liver function test patterns.
• Steroid therapy demonstrated high efficacy (approx. 90%) in lupoid hepatitis and lupoid type CAH, with lower efficacy in other CAH types.
• Autoimmune hepatitis had the lowest cumulative survival rates among CAH types.
• High serum bilirubin levels correlated with poorer survival; steroid duration and immunosuppressant dosage impacted prognosis.

Conclusions:

• Lupoid hepatitis and lupoid type CAH are distinct entities within autoimmune liver disease, predominantly affecting females.
• Steroid therapy is highly effective for lupoid hepatitis and lupoid type CAH, significantly impacting survival.
• Prognosis in autoimmune hepatitis is influenced by disease severity (bilirubin levels) and treatment parameters (steroid duration, immunosuppressant dosage).